211 related articles for article (PubMed ID: 30823906)
21. High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.
Melling N; Rashed M; Schroeder C; Hube-Magg C; Kluth M; Lang D; Simon R; Möller-Koop C; Steurer S; Sauter G; Jacobsen F; Büscheck F; Wittmer C; Clauditz T; Krech T; Tsourlakis MC; Minner S; Huland H; Graefen M; Budäus L; Thederan I; Salomon G; Schlomm T; Wilczak W
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146062
[TBL] [Abstract][Full Text] [Related]
22. Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy.
Minner S; Hager D; Steurer S; Höflmayer D; Tsourlakis MC; Möller-Koop C; Clauditz TS; Hube-Magg C; Luebke AM; Simon R; Sauter G; Göbel C; Weidemann S; Lebok P; Dum D; Fraune C; Izbicki J; Burandt E; Schlomm T; Huland H; Heinzer H; Haese A; Graefen M; Heumann A
Neoplasia; 2019 Sep; 21(9):872-881. PubMed ID: 31382165
[TBL] [Abstract][Full Text] [Related]
23. Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.
Burdelski C; Borcherding L; Kluth M; Hube-Magg C; Melling N; Simon R; Möller-Koop C; Weigand P; Minner S; Haese A; Michl HU; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Lebok P; Steurer S; Izbicki JR; Sauter G; Krech T; Büscheck F; Clauditz T; Schlomm T; Wilczak W
Oncotarget; 2017 May; 8(19):31494-31508. PubMed ID: 28415558
[TBL] [Abstract][Full Text] [Related]
24. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
[TBL] [Abstract][Full Text] [Related]
25. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.
Yoshimoto M; Ding K; Sweet JM; Ludkovski O; Trottier G; Song KS; Joshua AM; Fleshner NE; Squire JA; Evans AJ
Mod Pathol; 2013 Mar; 26(3):435-47. PubMed ID: 23018874
[TBL] [Abstract][Full Text] [Related]
26. High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Weidemann SA; Sauer C; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Fraune C; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Heumann A
BMC Cancer; 2019 Oct; 19(1):944. PubMed ID: 31606028
[TBL] [Abstract][Full Text] [Related]
27. Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients.
Büscheck F; Sulimankhil M; Melling N; Höflmayer D; Hube-Magg C; Simon R; Göbel C; Hinsch A; Weidemann S; Izbicki JR; Jacobsen F; Mandelkow T; Blessin NC; Möller-Koop C; Lutz F; Viehweger F; Möller K; Sauter G; Lennartz M; Burandt E; Lebok P; Minner S; Bonk S; Huland H; Graefen M; Schlomm T; Fraune C
Cancer Med; 2020 Feb; 9(4):1409-1418. PubMed ID: 31893572
[TBL] [Abstract][Full Text] [Related]
28. Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers.
Burdelski C; Bujupi E; Tsourlakis MC; Hube-Magg C; Kluth M; Melling N; Lebok P; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Simon R; Schlomm T; Steurer S; Krech T
PLoS One; 2015; 10(6):e0128525. PubMed ID: 26030748
[TBL] [Abstract][Full Text] [Related]
29. Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.
Kluth M; Hesse J; Heinl A; Krohn A; Steurer S; Sirma H; Simon R; Mayer PS; Schumacher U; Grupp K; Izbicki JR; Pantel K; Dikomey E; Korbel JO; Plass C; Sauter G; Schlomm T; Minner S
Mod Pathol; 2013 Jul; 26(7):975-83. PubMed ID: 23370768
[TBL] [Abstract][Full Text] [Related]
30. Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer.
Burdelski C; Reiswich V; Hube-Magg C; Kluth M; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wittmer C; Huland H; Simon R; Schlomm T; Sauter G; Steurer S
Clin Cancer Res; 2015 Aug; 21(15):3471-9. PubMed ID: 25925890
[TBL] [Abstract][Full Text] [Related]
31. Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions.
Bernreuther C; Daghigh F; Möller K; Hube-Magg C; Lennartz M; Lutz F; Rico SD; Fraune C; Dum D; Luebke AM; Eichenauer T; Möller-Koop C; Schlomm T; Wittmer C; Huland H; Heinzer H; Graefen M; Haese A; Burandt E; Tsourlakis MC; Clauditz TS; Höflmayer D; Izbicki JR; Simon R; Sauter G; Minner S; Steurer S; Meiners J
Pathol Oncol Res; 2020 Oct; 26(4):2709-2722. PubMed ID: 32677026
[TBL] [Abstract][Full Text] [Related]
32. Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers.
Luebke AM; Ricken W; Kluth M; Hube-Magg C; Schroeder C; Büscheck F; Möller K; Dum D; Höflmayer D; Weidemann S; Fraune C; Hinsch A; Wittmer C; Schlomm T; Huland H; Heinzer H; Graefen M; Haese A; Minner S; Simon R; Sauter G; Wilczak W; Meiners J
Int J Cancer; 2020 Jul; 147(2):575-583. PubMed ID: 32150281
[TBL] [Abstract][Full Text] [Related]
33. Strong expression of the neuronal transcription factor FOXP2 is linked to an increased risk of early PSA recurrence in ERG fusion-negative cancers.
Stumm L; Burkhardt L; Steurer S; Simon R; Adam M; Becker A; Sauter G; Minner S; Schlomm T; Sirma H; Michl U
J Clin Pathol; 2013 Jul; 66(7):563-8. PubMed ID: 23559350
[TBL] [Abstract][Full Text] [Related]
34. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion.
Fraune C; Harms L; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Möller K; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Sauter G; Weidemann S; Lebok P; Dum D; Kind S; Minner S; Izbicki JR; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Schroeder C
Mol Med; 2020 Mar; 26(1):24. PubMed ID: 32143573
[TBL] [Abstract][Full Text] [Related]
36. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
[TBL] [Abstract][Full Text] [Related]
37. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
38. TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S; Mayer PS; Adam M; Krohn A; Koop C; Ospina-Klinck D; Tehrani AA; Simon R; Tennstedt P; Graefen M; Wittmer C; Brors B; Plass C; Korbel J; Weischenfeldt J; Sauter G; Huland H; Tsourlakis MC; Minner S; Schlomm T
Eur Urol; 2014 Dec; 66(6):978-81. PubMed ID: 25015038
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
40. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
Tsourlakis MC; Eleftheriadou A; Stender A; Weigand P; Grupp K; Hube-Magg C; Kluth M; Schroeder C; Steurer S; Hinsch A; Luebke A; Angerer A; Wittmer C; Friedrich E; Göbel C; Büscheck F; Heinzer H; Graefen M; Simon R; Sauter G; Wilczak W; Minner S; Schlomm T; Jacobsen F
Carcinogenesis; 2017 Dec; 38(12):1180-1187. PubMed ID: 29029032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]